Pramipexole was cleared for marketing in the U.S. on July 10, 1997. This is the first new anti-Parkinsonian drug to hit the market in the past six years. Pramipexole can be used to treat all stages of Parkinson's disease. Pramipexole, when given concomitantly with levodopa, improves patients with advanced Parkinson's disease and levodopa-induced motor fluctuation.